Kevin Lilly is an established leader in the healthcare technology sphere who guided sales with the MiMedx Group for four years as senior vice president. The regenerative medicine enterprise Kevin Lilly helped expand maintains a leading industry presence with patent-protected processes that place placental tissue allografts in diverse healthcare sectors.
In March 2021, MiMedx announced that it had entered into a significant group purchasing agreement with Premier Inc. spanning its amniotic tissue portfolio. Administered through the SURPASS (Synergizing for Unparalleled Results in Procurement and Strategic Sourcing) program, the agreement will provide an array of regenerative skin-grafting products to SURPASS members at special terms and pricing.
As the CEO of MiMedx described it, this places MiMedx at the forefront when it comes to providing advanced wound care patients with access to PURION processed tissue technologies. At the same time, the agreement will make placental biologics more affordable to a wider range of patients living with hard-to-heal and chronic wounds.
